"we had yet to model any financial contribution from HemoDefend given the relatively early stage of development of the product and little visibility as to potential commercialization timelines"
"today's announcement does not provide substantially more insight into probabilities of eventual commercialization or related timelines"
in other words, getting the contract award was meaningful in that it keeps hope alive but, as Zacks points out, the Hemodefend idea has been on the radar screen of potential partners for almost two years without attracting any development money...
Fudsy, you are pointing out the obvious. Where did the company mention commercialization timeline or any other hyperbole regarding the announcement? Zacks points that out.
You are so concerned about acting like a girlyman, that any announcement the company makes ranks another uninformed tirade by you.
As I mentioned, I appreciated Chan announcing the news, if to only give you some new subject matter. I knew you'd "run it into the ground" ............. we're there.
When the interim dosing results are known and released, there should be a follow up announcement by partner(s) who have already done their due diligence in advance. They are all waiting for confirmation.
"Relative to potential partners, CTSO most recently noted (on the August business update call) that they are in active discussions with about 20 companies for commercialization of CytoSorb and Hemodefend, combined. For HemoDefend, CTSO is looking at companies involved in blood collection and transfusions. As an example, they had previously mentioned blood bag manufacturers as one type of potential partner (for the "beads in a bag" configuration)."